San Diego-based mostly Viking Therapeutics marked alone as a significant competitor within the weight loss drug current market in February just after revealing promising information from a mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified being a weekly injection and in